FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019440432> ?p ?o ?g. }

• W2019440432 endingPage "3995" @default.
• W2019440432 startingPage "3988" @default.
• W2019440432 abstract "Pertuzumab is a monoclonal antibody that binds to HER2 and is used in combination with another HER2-specific monoclonal antibody, trastuzumab, for the treatment of HER2+ metastatic breast cancer. Pertuzumab binds to an HER2 binding site distinct from that of trastuzumab, and its affinity is enhanced when trastuzumab is present. We aim to exploit this enhanced affinity of pertuzumab for its HER2 binding epitope and adapt this antibody as a PET imaging agent by radiolabeling with (89)Zr to increase the sensitivity of HER2 detection in vivo. Here, we investigate the biodistribution of (89)Zr-pertuzumab in HER2-expressing BT-474 and HER2-nonexpressing MDA-MB-231 xenografts to quantitatively assess HER2 expression in vivo. In vitro cell binding studies were performed resulting in retained immunoreactivity and specificity for HER2-expressing cells. In vivo evaluation of (89)Zr-pertuzumab was conducted in severely combined immunodeficient mice, subcutaneously inoculated with BT-474 and MDA-MB-231 cells. (89)Zr-pertuzumab was systemically administered and imaged at 7 days postinjection (p.i.) followed by terminal biodistribution studies. Higher tumor uptake was observed in BT-474 compared to MDA-MB-231 xenografts with 47.5 ± 32.9 and 9.5 ± 1.7% ID/g, respectively at 7 days p.i (P = 0.0009) and blocking studies with excess unlabeled pertuzumab showed a 5-fold decrease in BT-474 tumor uptake (P = 0.0006), confirming the in vivo specificity of this radiotracer. Importantly, we observed that the tumor accumulation of (89)Zr-pertuzumab was increased in the presence of unlabeled trastuzumab, at 173 ± 74.5% ID/g (P = 0.01). Biodistribution studies correlate with PET imaging quantification using max SUV (r = 0.98, P = 0.01). Collectively, these results illustrate that (89)Zr-pertuzumab as a PET imaging agent may be beneficial for the quantitative and noninvasive assessment of HER2 expression in vivo especially for patients undergoing trastuzumab therapy." @default.
• W2019440432 created "2016-06-24" @default.
• W2019440432 creator A5007600636 @default.
• W2019440432 creator A5036420670 @default.
• W2019440432 creator A5055646458 @default.
• W2019440432 creator A5063576128 @default.
• W2019440432 creator A5066526316 @default.
• W2019440432 creator A5071656979 @default.
• W2019440432 creator A5075304112 @default.
• W2019440432 date "2014-08-05" @default.
• W2019440432 modified "2023-10-15" @default.
• W2019440432 title "Evaluation of ⁸⁹Zr-pertuzumab in Breast Cancer Xenografts" @default.
• W2019440432 cites W1978863320 @default.
• W2019440432 cites W1982322665 @default.
• W2019440432 cites W2005973928 @default.
• W2019440432 cites W2023488625 @default.
• W2019440432 cites W2025497179 @default.
• W2019440432 cites W2037409533 @default.
• W2019440432 cites W2054706573 @default.
• W2019440432 cites W2058426435 @default.
• W2019440432 cites W2065023097 @default.
• W2019440432 cites W2068430088 @default.
• W2019440432 cites W2097277023 @default.
• W2019440432 cites W2098694743 @default.
• W2019440432 cites W2104239861 @default.
• W2019440432 cites W2105271102 @default.
• W2019440432 cites W2108182027 @default.
• W2019440432 cites W2110635076 @default.
• W2019440432 cites W2115269770 @default.
• W2019440432 cites W2122767481 @default.
• W2019440432 cites W2126831997 @default.
• W2019440432 cites W2129922868 @default.
• W2019440432 cites W2145038323 @default.
• W2019440432 cites W2150228337 @default.
• W2019440432 doi "https://doi.org/10.1021/mp500323d" @default.
• W2019440432 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4224522" @default.
• W2019440432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25058168" @default.
• W2019440432 hasPublicationYear "2014" @default.
• W2019440432 type Work @default.
• W2019440432 sameAs 2019440432 @default.
• W2019440432 citedByCount "62" @default.
• W2019440432 countsByYear W20194404322015 @default.
• W2019440432 countsByYear W20194404322016 @default.
• W2019440432 countsByYear W20194404322017 @default.
• W2019440432 countsByYear W20194404322018 @default.
• W2019440432 countsByYear W20194404322019 @default.
• W2019440432 countsByYear W20194404322020 @default.
• W2019440432 countsByYear W20194404322021 @default.
• W2019440432 countsByYear W20194404322022 @default.
• W2019440432 countsByYear W20194404322023 @default.
• W2019440432 crossrefType "journal-article" @default.
• W2019440432 hasAuthorship W2019440432A5007600636 @default.
• W2019440432 hasAuthorship W2019440432A5036420670 @default.
• W2019440432 hasAuthorship W2019440432A5055646458 @default.
• W2019440432 hasAuthorship W2019440432A5063576128 @default.
• W2019440432 hasAuthorship W2019440432A5066526316 @default.
• W2019440432 hasAuthorship W2019440432A5071656979 @default.
• W2019440432 hasAuthorship W2019440432A5075304112 @default.
• W2019440432 hasBestOaLocation W20194404321 @default.
• W2019440432 hasConcept C121608353 @default.
• W2019440432 hasConcept C126322002 @default.
• W2019440432 hasConcept C150903083 @default.
• W2019440432 hasConcept C153911025 @default.
• W2019440432 hasConcept C159654299 @default.
• W2019440432 hasConcept C185592680 @default.
• W2019440432 hasConcept C195616568 @default.
• W2019440432 hasConcept C202751555 @default.
• W2019440432 hasConcept C203014093 @default.
• W2019440432 hasConcept C207001950 @default.
• W2019440432 hasConcept C2777807558 @default.
• W2019440432 hasConcept C2779786085 @default.
• W2019440432 hasConcept C2781164504 @default.
• W2019440432 hasConcept C502942594 @default.
• W2019440432 hasConcept C530470458 @default.
• W2019440432 hasConcept C542903549 @default.
• W2019440432 hasConcept C55493867 @default.
• W2019440432 hasConcept C71924100 @default.
• W2019440432 hasConcept C86803240 @default.
• W2019440432 hasConceptScore W2019440432C121608353 @default.
• W2019440432 hasConceptScore W2019440432C126322002 @default.
• W2019440432 hasConceptScore W2019440432C150903083 @default.
• W2019440432 hasConceptScore W2019440432C153911025 @default.
• W2019440432 hasConceptScore W2019440432C159654299 @default.
• W2019440432 hasConceptScore W2019440432C185592680 @default.
• W2019440432 hasConceptScore W2019440432C195616568 @default.
• W2019440432 hasConceptScore W2019440432C202751555 @default.
• W2019440432 hasConceptScore W2019440432C203014093 @default.
• W2019440432 hasConceptScore W2019440432C207001950 @default.
• W2019440432 hasConceptScore W2019440432C2777807558 @default.
• W2019440432 hasConceptScore W2019440432C2779786085 @default.
• W2019440432 hasConceptScore W2019440432C2781164504 @default.
• W2019440432 hasConceptScore W2019440432C502942594 @default.
• W2019440432 hasConceptScore W2019440432C530470458 @default.
• W2019440432 hasConceptScore W2019440432C542903549 @default.
• W2019440432 hasConceptScore W2019440432C55493867 @default.
• W2019440432 hasConceptScore W2019440432C71924100 @default.
• W2019440432 hasConceptScore W2019440432C86803240 @default.
• W2019440432 hasFunder F4320306084 @default.

• next